MoonLake Immunotherapeutics
MLTX
MLTX
130 hedge funds and large institutions have $2.77B invested in MoonLake Immunotherapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 52 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
4% less funds holding
Funds holding: 136 → 130 (-6)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
29% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 52
Holders
130
Holding in Top 10
6
Calls
$39.6M
Puts
$37.7M
Top Buyers
| 1 | +$56.2M | |
| 2 | +$30.2M | |
| 3 | +$20.7M | |
| 4 |
VPC
Vestal Point Capital
New York
|
+$14.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14M |
Top Sellers
| 1 | -$34.7M | |
| 2 | -$24.3M | |
| 3 | -$17.2M | |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$17M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.7M |